%0 Journal Article %A Pedro J. Gonzalez-Cabrera %A Robert J. Gaivin %A June Yun %A Sean A. Ross %A Robert S. Papay %A Dan F. McCune %A Boyd R. Rorabaugh %A Dianne M. Perez %T Genetic Profiling of α1-Adrenergic Receptor Subtypes by Oligonucleotide Microarrays: Coupling to Interleukin-6 Secretion but Differences in STAT3 Phosphorylation and gp-130 %D 2003 %R 10.1124/mol.63.5.1104 %J Molecular Pharmacology %P 1104-1116 %V 63 %N 5 %X α1-Adrenoceptor subtypes (α1A-, α1B-, α1D-) are known to couple to similar signaling pathways, although differences among the subtypes do exist. As a more sensitive assay, we used oligonucleotide microarrays to identify gene expression changes in Rat-1 fibroblasts stably expressing each individual subtype. We report the gene expressions that change by at least a factor of 2 or more. Gene expression profiles significantly changed equally among all three subtypes, despite the unequal efficacy of the inositol phosphate response. Gene expressions were clustered into cytokines/growth factors, transcription factors, enzymes, and extracellular matrix proteins. There were also a number of individual subtype-specific changes in gene expression, suggesting a link to independent pathways. In addition, all three α1-AR subtypes robustly stimulated the transcription of the prohypertrophic cytokine interleukin (IL)-6, but differentially altered members of the IL-6 signaling pathway (gp-130 and STAT3). This was confirmed by measurement of secreted IL-6, activated STAT3, and gp-130 levels. Activation of STAT3 Tyr705 phosphorylation by the α1-ARs was not through IL-6 activation but was synergistic with IL-6, suggesting direct effects. Interestingly, α1B-AR stimulation caused the dimerization-dependent phosphorylation of Tyr705 on STAT3 but did not activate the transcriptional-dependent phosphorylation of Ser727. The α1B-AR also constitutively down-regulated the protein levels of gp-130. These results suggest that the α1B-AR has differential effects on the phosphorylation status of the STAT3 pathway and may not be as prohypertrophic as the other two subtypes. The American Society for Pharmacology and Experimental Therapeutics %U https://molpharm.aspetjournals.org/content/molpharm/63/5/1104.full.pdf